One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

The COVID-19 pandemic revealed how ill-prepared the world was to detect and respond to global health threats. With over 7·1 million lives lost,1 more than US$4·7 trillion in economic damage,2 profound ...

Janus kinase (JAK) inhibitors are associated with decreased mortality and fewer serious adverse events among adults hospitalized with COVID-19.